Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 101–200 of 666
Insulin Pump Use in Type 2 Diabetes
Bode, B. W. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0192 · Cited by 55
Insulin treatment for type 2 diabetes: When to start, which to use
Hamaty, M. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10051 · Cited by 55
Prato, S. D., Nicolucci, A., Lovagnini-Scher, A. C., Turco, S., Leotta, S., & Vespasiani, G. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0163 · Cited by 54
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
Currie, C. J., & Johnson, J. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01469.x · Cited by 54
Ji, L., Zhang, P., Zhu, D., Li, X., Ji, J., Lu, J., Guo, X., Jia, W., Weng, J., Wu, Y., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12886 · Cited by 57
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 59
Insulin and atherosclerosis: How are they related?
Monnier, L., Hanefeld, M., Schnell, O., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.001 · Cited by 66
“[4] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF,”
BackgroundCrasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.067926 · Cited by 57
Self-citationCommon Standards of Basal Insulin Titration in T2DM
Arnolds, S., Heise, T., Flacke, F., & Sieber, J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700323 · Cited by 55
Riddle, M. C., Vlajnic, A., Zhou, R., & Rosenstock, J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12096 · Cited by 52
Dhital, S. M., Shenker, Y., Meredith, M., & Davis, D. B. (2012) · Endocrine Practice · doi:10.4158/ep11371.or · Cited by 49
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 48
“[68] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.”
BackgroundPontiroli, A. E., Miele, L., & Morabito, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01543.x · Cited by 48
Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
Ceriello, A. (2010) · Diabetes Care · doi:10.2337/dc10-0634 · Cited by 49
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Charbonnel, B. H., Bertolini, M., Tinahones, F. J., Puig‐Domingo, M., & Davies, M. J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.007 · Cited by 51
“Results of the 4T study reported that approximately two-thirds of patients who received a basal–prandial insulin regimen, subsequent to loss of glycemic control on basal insulin plus OADs, achieved a target HbA1c of b7% (Holman et al., 2009).”
BackgroundSelf-citationInsulin therapy, weight gain and prognosis
Hodish, I. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13367 · Cited by 54
Sinha, V. P., Choi, S. L., Soon, D., Mace, K. F., Yeo, K. P., Lim, S., & Howey, D. C. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.276 · Cited by 54
“In general, basal insulins seek to achieve some combination of the following advantages: a prolonged activity profile that supports true once‐daily dosing in both type 1 and type 2 diabetes patients, the absence of insulin activity peaks that result in hypoglycemia, reproducible absorption kinetics, and a solution‐bas…”
BackgroundHermanns, N., Kulzer, B., Maier, B., Mahr, M., & Haak, T. (2011) · Patient Education and Counseling · doi:10.1016/j.pec.2011.05.017 · Cited by 50
Hypoglycaemia: current management and controversies
Choudhary, P., & Amiel, S. A. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.068197 · Cited by 47
Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, J. L., Menéndez, S. A., NúñezfiCortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65006-5 · Cited by 61
Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 73
Davies, M. J., Russell-Jones, D. L., Selam, J. L., Bailey, T. S., Kerényi, Z., Luo, J., Bue‐Valleskey, J. M., Iványi, T., Hartman, M. L., Jacobson, J. G., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12712 · Cited by 48
Self-citationInsulin Detemir: A Review of its Use in the Management of Diabetes Mellitus
Keating, G. M. (2012) · Drugs · doi:10.2165/11470200-000000000-00000 · Cited by 55
Khunti, K., Davies, M. J., & Kalra, S. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12053 · Cited by 48
“In the Treating to Target in Type 2 Diabetes (4-T) study, administration of biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if needed), resulted in reasonable efficacy across treatment groups, although fewer hypoglycaemic episodes and less weig…”
BackgroundSelf-citationLawton, J., Jenkins, N., Darbyshire, J. L., Farmer, A. A., Holman, R. R., & Hallowell, N. (2011) · Social Science & Medicine · doi:10.1016/j.socscimed.2011.11.012 · Cited by 53
“Despite these regulatory procedures being put in place, there was limited attainment of the trial’s primary endpoint across all three arms (Holman et al., 2009).”
BackgroundSelf-citationControl glucémico en pacientes con diabetes mellitus tipo 2 en España
Pérez, A., Mediavilla, J., Miñambres, I., & Alsina, D. G.-S. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.05.028 · Cited by 56
Owens, D. R. (2012) · Diabetic Medicine · doi:10.1111/dme.12019 · Cited by 46
Mitchell, B. D., Vietri, J., Zagar, A. J., Curtis, B. H., & Reaney, M. D. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-59 · Cited by 48
“; licensee BioMed Centra Commons Attribution License (http://creativec reproduction in any medium, provided the or However, even patients who are placed on intensive treatment often do not achieve adequate control, a result observed in both clinical trials and observational studies [11-14].”
BackgroundAlsahli, M., & Gerich, J. E. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.07.002 · Cited by 53
Vora, J., Cohen, N., Evans, M., Hockey, A., Speight, J., & Whately‐Smith, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12528 · Cited by 44
The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial
Buse, J. B., Wolffenbuttel, B. H. R., Herman, W. H., Hippler, S. E., Martin, S., Jiang, H. H., Shenouda, S. K., & Fahrbach, J. L. (2011) · Diabetes Care · doi:10.2337/dc10-1701 · Cited by 49
2022 Guidelines on the management of patients with diabetes. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2022) · Current Topics in Diabetes · doi:10.5114/ctd/146259 · Cited by 69
Update on Insulin Therapy for Type 2 Diabetes
Donner, T. W., & Muñoz, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2202 · Cited by 49
“52%) than those targeting a FPG of less than 126 mg/dl, with mildly higher rates of hypoglycemia (11, 12).”
BackgroundMethodInfluentialRSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Kumar, S., Jang, H. C., Demirağ, N. G., Skjøth, T. V., Endahl, L. A., & Bode, B. W. (2016) · Diabetic Medicine · doi:10.1111/dme.13125 · Cited by 41
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 42
Hope, S. V., Knight, B., Shields, B. M., Hill, A. V., Choudhary, P., Strain, W. D., McDonald, T. J., & Jones, A. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4449-2 · Cited by 52
“To assess whether differences between groups were due to confounding by differences in clinical features associated with hypoglycaemia and insulin type [21], we assessed the OR (proportions, logistic regression) and rate ratio (questions 5 Diabetologia”
BackgroundMethodInsulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Balancing Hypoglycemia and Glycemic Control: A Public Health Approach for Insulin Safety
POGACH, L. M., & Aron, D. C. (2010) · JAMA · doi:10.1001/jama.2010.655 · Cited by 41
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
“When starting insulin, it has been reported that starting with basal insulin was associated with less weight gain and hypoglycemia in comparison to starting with prandial bolus insulin or pre-mixed insulin (109).”
ResultBasal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 44
Hypoglycemia: Minimizing its impact in type 2 diabetes
Moghissi, E., Ismail-Beigi, F., & Devine, R. C. (2013) · Endocrine Practice · doi:10.4158/ep13005.ra · Cited by 39
Bowering, K., Reed, V. A., Felício, J., Landry, J., Liang, J., & Oliveira, J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03722.x · Cited by 39
Owens, D. R., Traylor, L., Dain, M., & Landgraf, W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.003 · Cited by 41
“[8] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.”
BackgroundIntensified glucose control in type 2 diabetes—whose agenda?
Yudkin, J. S., Richter, B., & Gale, E. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61112-9 · Cited by 39
The FLAT-SUGAR Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-2689 · Cited by 39
Wang, C., Mamza, J., & IDRIS, I. R. (2015) · Diabetic Medicine · doi:10.1111/dme.12694 · Cited by 38
Can a Tool That Automates Insulin Titration Be a Key to Diabetes Management?
Bergenstal, R. M., Bashan, E., McShane, M., Johnson, M. L., & Hodish, I. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0303 · Cited by 43
Edelman, S. V., Liu, R., Johnson, J. L., & Glass, L. C. (2014) · Diabetes Care · doi:10.2337/dc13-2664 · Cited by 39
LaSalle, J. R., & Berria, R. (2013) · PubMed · Cited by 38
Miya, A., Nakamura, A., Miyoshi, H., Cho, K. Y., Nagai, S., Kurihara, Y., Aoki, S., Taguri, M., Terauchi, Y., & Atsumi, T. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12654 · Cited by 37
Gordon, J. P., Pockett, R. D., Tetlow, A., McEwan, P., & Home, P. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02520.x · Cited by 38
Newer insulin analogs: advances in basal insulin replacement
Zinman, B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12068 · Cited by 42
“The incidence of hypoglycaemia with insulin therapy increases with duration of diabetes [22] and may become problematic in patients on basal–bolus insulin therapy [23].”
BackgroundZhang, C.-Y., Sun, A.-J., Zhang, S.-N., Wu, C.-N., Fu, M.-Q., Xia, G., Wang, K.-Q., Zou, Y.-Z., & Ge, J.-B. (2010) · Annals of Medicine · doi:10.3109/07853891003796752 · Cited by 37
The management of diabetes in terminal illness related to cancer
King, E. J., Haboubi, H., Evans, D., Baker, I. A., Bain, S. C., & Stephens, J. W. (2011) · QJM · doi:10.1093/qjmed/hcr167 · Cited by 37
Battista, M.-C., Labonté, M., Ménard, J., Jean-Denis, F., Houde, G., Ardilouze, J.-L., & Perron, P. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-025 · Cited by 36
Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?
Meneghini, L. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.011 · Cited by 36
Abrahamson, M. J., & Peters, A. L. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.699715 · Cited by 38
Biosynthetic Human Insulin and Insulin Analogs
Rodbard, H. W., & Rodbard, D. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001089 · Cited by 46
Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review
Noh, R. M., Graveling, A. J., & Frier, B. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.589835 · Cited by 42
Ekström, N., Miftaraj, M., Svensson, A. ‐., Sundell, K. A., Cederholm, J., Zethelius, B., Guðbjörnsdóttir, S., & Eliasson, B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01591.x · Cited by 34
“0% [21].”
Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial
Jenkins, N., Hallowell, N., Farmer, A. A., Holman, R. R., & Lawton, J. (2010) · Diabetes Care · doi:10.2337/dc10-0494 · Cited by 35
Self-citationJain, S. M., Mao, X.-Q., Escalante-Pulido, M., Ворохобина, Н. В., López, I. S., & Ilag, L. L. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01287.x · Cited by 35
“The 3-year results of the Treating to Target in Type 2 Diabetes (4-T) study suggest that most patients are likely to need a second type of insulin [10].”
BackgroundPharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes
Gram, J., Henriksen, J. E., Grodum, E., Juhl, H., Hansen, T. B., Christiansen, C., Yderstræde, K., Gjessing, H., Hansen, H. M., Vestergaard, V., et al. (2011) · Diabetes Care · doi:10.2337/dc10-0531 · Cited by 35
“A similar high proportion of responders have only rarely been achieved in other randomized trials of insulin treatment in type 2 diabetes besides in the advanced insulin regimens groups in the 4T trial (6).”
BackgroundGlycemic control in patients with type 2 diabetes mellitus in Spain
Pérez, A., Mediavilla, J., Miñambres, I., & González-Segura, D. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.05.007 · Cited by 35
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Dolovich, L., & Houlden, R. L. (2012) · PubMed Central · Cited by 42
Liraglutide for the treatment of type 2 diabetes
Shyangdan, D., Cummins, E., Royle, P., & Waugh, N. R. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1/09 · Cited by 39
Hanefeld, M., Monnier, L., Schnell, O., & Owens, D. R. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0153-3 · Cited by 37
“6 kg in the basal insulin (insulin detemir) treated group [42, 78].”
BackgroundAnyanwagu, U., Mamza, J., Gordon, J. P., Donnelly, R., & IDRIS, I. R. (2017) · Diabetic Medicine · doi:10.1111/dme.13518 · Cited by 34
Balkau, B., Calvi-Gries, F., Freemantle, N., Vincent, M., Pilorget, V., & Home, P. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.034 · Cited by 35
Wu, T., Betty, B., Downie, M. R., Khanolkar, M., Kilov, G., Orr‐Walker, B., Senator, G. B., & Fulcher, G. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0116-0 · Cited by 34
Asche, C. V., Bode, B. W., Busk, A. K., & Nair, S. R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01487.x · Cited by 34
“7 episodes per patient year Holman [20] Biphasic insulin NR 49.”
BackgroundInfluentialFactors Associated with Diabetes-Related Distress in Type 2 Diabetes Mellitus Patients
Bhaskara, G., Budhiarta, A. A. G., Gotera, W., Saraswati, M. R., Dwipayana, I. M. P., Semadi, I. M. S., Nugraha, I. B. A., Wardani, I. A. K., & Suastika, K. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s363431 · Cited by 45
“This makes the patient feel guilty about failing to treat his/her diabetes.(24) Third, insulin is more expensive than the OAD regiment.”
BackgroundComplementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
“5%) will require insulin to control their hyperglycemia [29].”
BackgroundLawton, J., Jenkins, N., Darbyshire, J. L., Holman, R. R., Farmer, A. A., & Hallowell, N. (2011) · Trials · doi:10.1186/1745-6215-12-108 · Cited by 34
“At three years, the corresponding proportions were 32%, 45% and 43% [4,5].”
BackgroundSelf-citationImpact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 34
“Diabetes (4-T) trial, which compared glycemic efficacy, weight fluctuations and hypoglycemic events using 3 different insulin preparations in 708 participants who were suboptimally controlled with metformin and sulfonylurea, basal and prandial insulin therapies demonstrated superior A1C-level control relative to the b…”
BackgroundVora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 31
Basal Plus Basal–Bolus Approach in Type 2 Diabetes
Ampudia‐Blasco, F. J., Rossetti, P., & Ascaso, J. F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0001 · Cited by 35
Oğuz, A., Benroubi, M., Brismar, K., Melo, P., Morar, C., Cleall, S., Giaconia, J. M., & Schmitt, H. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803053 · Cited by 30
Setty, S. G., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133716 · Cited by 37
Self-citationJenkins, N., Hallowell, N., Farmer, A. A., Holman, R. R., & Lawton, J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03200.x · Cited by 31
“At the end of the trial, less than half achieved target glycaemic control (biphasic 32%, prandial 45%, basal 43%) [9, 10].”
BackgroundMethodSelf-citationSelf-Monitoring of Blood Glucose: A Prerequisite for Diabetes Management in Outcome Trials
Schnell, O., Hanefeld, M., & Monnier, L. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814528134 · Cited by 39
“9% of those on biphasic insulin.(24) It highlights how SMBG enables patients to clearly visualize the impact of various insulin treatment approaches on HbA1c levels and provides useful information that can be used to inform decisions about treatment optimization.”
BackgroundMonnier, L., Colette, C., Michel, F., Cristol, J., & Owens, D. R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1174 · Cited by 29
Krzymień, J., & Ładyżyński, P. (2019) · Nutrients · doi:10.3390/nu11030607 · Cited by 42
Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
“preferred due to similar efficacy, less weight gain, and less hypoglycemia [9].”
BackgroundNear normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 30
Hermanns, N., Ehrmann, D., Schall, S., Maier, B., Haak, T., & Kulzer, B. (2017) · Diabetic Medicine · doi:10.1111/dme.13346 · Cited by 31
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Baruah, M., Kalra, S., Unnikrishnan, A., Raza, S., Somasundaram, N. P., John, M., Katulanda, P., Shrestha, D., Bantwal, G., Sahay, R. K., et al. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81935 · Cited by 32
“6% of patients who were initiated on basal analogue detemir required additional prandial insulin during 3 years of follow-up when titrations were done to achieve a tight glycemic control.[62]”
BackgroundSone, H., Kaneko, T., Shiki, K., Tachibana, Y., Pfarr, E., Lee, J., & Tajima, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13909 · Cited by 35
“Prior evidence has demonstrated that insulin doses typically need to be increased to maintain glycaemic control over time.(38,39) In the present study, two distinct treatment phases were employed: a 16-week period during which the insulin dose was fixed, to directly assess the drug effect, followed by a 36-week period…”
BackgroundValentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14979 · Cited by 28
“In the case of BMI, the return to baseline on initiation of basal insulin therapy may have been conservative, given that evidence from the 4 T trial has shown that initiation of basal insulin therapy was only associated with a modest increase in body weight.(31) F IGURE 1 Probabilistic sensitivity analysis acceptabili…”
ResultFrías, J. P., Bode, B. W., Bailey, T. S., Kipnes, M. S., Brunelle, R. L., & Edelman, S. V. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500410 · Cited by 29
Initiating insulin in patients with type 2 diabetes
Lau, A. N. C., Tang, T., Halapy, H., Thorpe, K. E., & Yu, C. H. Y. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110779 · Cited by 32
Consensus statement on insulin therapy in chronic kidney disease
Rajput, R., Sinha, B., Majumdar, S., Shunmugavelu, M., & Bajaj, S. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.032 · Cited by 33
Freeman, J. S. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2672 · Cited by 31
Rašlová, K. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10397 · Cited by 38
Khoo, C. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00108-9 · Cited by 36
Current insulin therapy in patients with type 2 diabetes: Results of the ADHOC survey in France
Penfornis, A., San-Galli, F., Cimino, L., & Huet, D. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.03.001 · Cited by 28
“Many factors come nto play when deciding at what point to begin insulin therpy and what type of insulin to use [4], but a recent study uggests that adding basal insulin offers the best efficacy-toafety ratio [5].”
BackgroundIn support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Kim, Y. G., Min, S. H., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.011 · Cited by 28
“However, intensification of the insulin regimen is commonly associated with an increased risk of hypoglycaemia and/or increased body weight (7).”
Background
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.